Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

5-Fluorouracil/folinate/oxaliplatin (Eloxatin) (FLOX [FOLFOX] regimen), given continuously or intermittently, in combination with cetuximab (Erbitux), in first-line treatment of metastatic colorectal cancer. A phase III multicenter trial.

Next Previous
X
Search
Trial Profile

5-Fluorouracil/folinate/oxaliplatin (Eloxatin) (FLOX [FOLFOX] regimen), given continuously or intermittently, in combination with cetuximab (Erbitux), in first-line treatment of metastatic colorectal cancer. A phase III multicenter trial.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms Nordic-VII

    • Most Recent Events

    • 21 Sep 2020 Results of meta analysis validating the efficacy and safety between Q2W vs. Q1W CET dosing presented at the 45th European Society for Medical Oncology Congress
    • 01 Aug 2017 Results evaluating the effect of cetuximab on health-related quality of life (HRQoL) in the NORDIC-VII trial on metastatic colorectal cancer (mCRC), published in the European Journal of Cancer.
    • 11 Apr 2017 Results of final survival analyses and extended RAS data published in the British Journal of Cancer.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top